Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04519437
Recruitment Status : Active, not recruiting
First Posted : August 19, 2020
Last Update Posted : December 2, 2020
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : October 25, 2021
Estimated Study Completion Date : October 25, 2021